EBOS Group Limited (ASX:EBO) shares were priced at $15.35 on 6 October 2026, up 2.61% on the day, and are down 41.05% over the past twelve months. The healthcare and animal care distributor released its FY26 results on 19 August 2026, covering the year ended 30 June 2026, with figures in Australian dollars.

Across the broader market, the S&P/ASX 200 Health Care index [XHJ] (INDEXASX: XHJ) stood at 31,982.20, up 0.63% (+200.50 points) as of 6 October, and is down 16% over the past year. Meanwhile, the S&P/ASX 200 stood at 8,735.70, up 0.57% (+49.30 points) at the same time, and is down 2.74% over the year.

Business Model and Operational Footprint

EBOS operates through two divisions. Healthcare, which generated $12,580 million of FY26 revenue, includes Symbion and Healthcare Distribution (Community Pharmacy, Hospital Medicines and Contract Logistics), Retail Pharmacy Brands, and Medical Technology. Animal Care, with Revenue of $907 million, covers branded and wholesale pet and veterinary products, including the Black Hawk, VitaPet and Lyppard businesses.

The company has dual listings on the NZX and ASX, with offices in Christchurch and Melbourne. Its footprint includes distribution centres, a TerryWhite Chemmart network with sales of about $2.9 billion, and a pharmacy network of 7,805 stores supported across brands, an increase of 86 on the prior year. EBOS completed a four-year, $360 million distribution centre renewal program during the year, with all major facilities now operational, including the new Perth Facility for healthcare logistics and the Onelink Auckland wholesale centre.

Sector Dynamics

EBOS pointed to continued Demand for GLP-1 and other high-value medicines as a driver of Community Pharmacy revenue, alongside competitive intensity in wholesale pharmacy and product mix effects on margins. Recent Community Service Obligation funding reforms were cited as a development relevant to the Healthcare segment.

Cost and currency conditions also featured in the period. The company noted elevated fuel and broader energy costs, which led to an update of its FY26 underlying EBITDA guidance on 22 April 2026, together with foreign exchange headwinds and softer Capital sales in South East Asia and Hong Kong.

FY26 Results Update

Group revenue rose 9.9% to $13,487 million and gross Operating Revenue rose 6.5% to $1,743 million. Underlying EBITDA increased 5.0% to $614 million, while the underlying EBITDA Margin eased from 4.8% to 4.6%. Underlying NPAT was $250 million, down 3.1%, which the company linked to higher depreciation, Amortisation and financing costs from its Investment cycle. Underlying Earnings Per Share were 121.7 cents, down 7.3%. Statutory NPAT was $225 million, up 4.7%. Leverage was 2.1 times, up from 1.9 times, and ROCE was 12.8%, down 20 basis points. The final Dividend was held at NZ 61.5 cents per share, a payout of 84.5% of underlying NPAT.

In Healthcare, underlying EBITDA rose 3.2% to $516 million, and the gross operating revenue margin moved from 12.3% to 11.9%. Community Pharmacy revenue increased 10.2% to $7.1 billion, with gross operating revenue up 4.3% to $613 million. Contract Logistics gross operating revenue rose 13.1% to $174 million, and Hospital Medicines, Consumables and Other revenue rose 4.3% to $3.8 billion. TerryWhite Chemmart network sales increased 9.2%, and owned Brand network sales rose 11%. Medical Technology revenue grew 5.5%, or 8.4% in constant currency, with four acquisitions completed, including K-Talyst.

In Animal Care, revenue increased 34.6% and underlying EBITDA rose 11.6% to $138 million, while the underlying EBITDA margin moved from 18.4% to 15.3% and the gross operating revenue margin from 32.0% to 26.8%, which the company linked to a mix shift toward wholesale after the SVS acquisition. The Paringa Pet Foods Acquisition was completed on 30 July 2026.

Growth Catalysts and Critical Operating Risks

For FY27, EBOS is targeting underlying EBITDA of $635 million to $655 million. It expects Capital Expenditure to fall to about $100 million, Depreciation and amortisation of $152 million to $162 million, and net finance costs of $138 million to $148 million. Leverage is expected to stay within the 1.7 to 2.3 times target range, modestly higher in the first half and lower in the second, with earnings and Cash Flow weighted to the second half. Productivity gains at the Kemps Creek distribution centre, targeted at a 30% uplift against the previous site by the end of FY27, and increased network utilisation are among the growth drivers named.

The release also points to risks and pressures. Fuel costs, foreign exchange movements and competitive dynamics in wholesale pharmacy were cited as cost and margin pressures. Gross operating revenue margins in Community Pharmacy and the Healthcare segment were lower than in FY25, and Community Pharmacy margins are expected to be influenced by CSO funding, product mix and competition. Growth in GLP-1 related sales was described as moderating, reflecting the larger base. Higher depreciation and financing costs are expected to continue, with the increase weighted to the first half.

The Bottom Line

EBOS ended FY26 with a share price down 41.05% over the year and results that show higher revenue and EBITDA alongside lower underlying NPAT and earnings per share, narrower margins and higher leverage. The completion of its $360 million distribution centre program and the FY27 EBITDA target of $635 million to $655 million frame the company's own outlook, with cost pressures, margin movements and wholesale competition identified among the matters it expects to manage.